文献速递胃肠动力与功能性疾病

Tenapanor治疗便秘型肠易激综合征的12周安慰剂对照3期试验(T3MPO-1)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
PubMed 文献 · Am J Gastroenterol · 2020-01-01

这项3期双盲试验将629例便秘型肠易激综合征(IBS-C)患者随机分配至Tenapanor 50 mg每日两次或安慰剂组治疗12周。意向治疗分析集(n=606)中,Tenapanor组达到主要终点(每周最严重腹痛平均降低≥30.0%且每周完全自发排便较基线增加≥1次、同一周内、12周治疗期内≥6周)的比例显著高于安慰剂组(27.0% vs 18.7%,P=0.020)。腹泻是最常见不良事件,Tenapanor组和安慰剂组分别有6.5%和0.7%的患者因腹泻停药。

要点

  • Tenapanor 50 mg每日两次可显著提高IBS-C患者腹痛和排便复合终点应答率。
  • 腹泻是最常见不良事件,6.5%的Tenapanor组患者因腹泻停药。
  • Tenapanor为IBS-C提供了潜在的新治疗选择。

核心结论

  • Tenapanor 50 mg每日两次可改善IBS-C症状且总体耐受性良好,提供潜在新治疗选择。

研究设计与样本

  • 3期双盲安慰剂对照试验(NCT02621892),629例IBS-C患者随机接受Tenapanor 50 mg每日两次或安慰剂治疗12周,随后4周随机撤药期。
  • 意向治疗分析集606例(96.3%):Tenapanor组307例,安慰剂组299例;533例(84.7%)完成12周治疗。
  • 意向治疗分析集平均年龄45岁,女性占81.4%。

主要发现

  • Tenapanor组达到主要终点的患者比例显著高于安慰剂组(27.0% vs 18.7%,P=0.020)。
  • Tenapanor组腹部症状和IBS整体症状也较安慰剂组改善(P<0.05)。
  • 腹泻是最常见不良事件,12周治疗期内Tenapanor组和安慰剂组因腹泻停药比例分别为6.5%和0.7%。

关键数值与推荐

  • 主要疗效变量:12周治疗期内≥6周同时满足每周最严重腹痛平均降低≥30.0%且每周完全自发排便较基线增加≥1次。

临床怎么用

  • Tenapanor 50 mg每日两次可作为IBS-C的潜在治疗选择,需关注腹泻及因腹泻停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 3, double-blind study (ClinicalTrials.gov identifier NCT02621892), patients with IBS-C were randomized to tenapanor 50 mg b.i.d. or placebo b.i.d. for 12 weeks followed by a 4-week randomized withdrawal period. The primary efficacy variable was the proportion of patients who reported a reduction in average weekly worst abdominal pain of ≥30.0% and an increase of ≥1 complete spontaneous bowel movement from baseline, both in the same week, for ≥6 weeks of the 12-week treatment period. RESULTS: Of the 629 randomized patients with IBS-C, 606 (96.3%) were included in the intention-to-treat analysis set (tenapanor: n = 307; placebo: n = 299) and 533 (84.7%) completed the 12-week treatment period. In the intention-to-treat analysis set (mean age 45 years, 81.4% women), a significantly greater proportion of patients treated with tenapanor met the primary endpoint than patients treated with placebo (27.0% vs 18.7%, P = 0.020). Abdominal symptoms and global symptoms of IBS also improved with tenapanor (P < 0.05 vs placebo). Diarrhea was the most commonly reported adverse event, resulting in study drug discontinuation in 6.5% and 0.7% of patients receiving tenapanor and placebo, respectively, during the 12-week treatment period. DISCUSSION: Tenapanor 50 mg b.i.d. improved IBS-C symptoms and was generally well tolerated, offering a potential new treatment option for patients with IBS-C.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chey WD, Lembo AJ, Rosenbaum DP, et al. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am J Gastroenterol. 2020. PMID: 31934897. doi:10.14309/ajg.0000000000000516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。